HN2002000254A - Uso de compuestos en un inhalador de polvo seco - Google Patents

Uso de compuestos en un inhalador de polvo seco

Info

Publication number
HN2002000254A
HN2002000254A HN2002000254A HN2002000254A HN2002000254A HN 2002000254 A HN2002000254 A HN 2002000254A HN 2002000254 A HN2002000254 A HN 2002000254A HN 2002000254 A HN2002000254 A HN 2002000254A HN 2002000254 A HN2002000254 A HN 2002000254A
Authority
HN
Honduras
Prior art keywords
compounds
dry powder
powder inhaler
formulation
piridines
Prior art date
Application number
HN2002000254A
Other languages
English (en)
Inventor
John Humphrey Michael
Robert Miller Paul
Trevor Shepherd Michael
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HN2002000254A publication Critical patent/HN2002000254A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA FORMULACION DE INHALACION, QUE COMPRENDE UN COMPUESTO SELECCIONADO ENTRE UNA CLASE PARTICULAR DE 5, 6-DIHIDRO-9H-PIRAZOLO [3, 4-C] -1, 2, 4-TRIAZOLO [4, 3-A] PIRIDINAS, QUE ES CAPAZ DE LIBERAR EL COMPUESTO EN FORMA DE PARTICULAS SOLIDAS FINAS EN EL PULMON, Y AL USO DE TAL FORMULACION EN EL TRATAMIENTO DE CIERTAS ENFERMEDADES RESPIRATORIAS.
HN2002000254A 2001-09-12 2002-10-11 Uso de compuestos en un inhalador de polvo seco HN2002000254A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0122031.8A GB0122031D0 (en) 2001-09-12 2001-09-12 Use of pde4 inhibitors in a dry powder inhaler

Publications (1)

Publication Number Publication Date
HN2002000254A true HN2002000254A (es) 2003-04-07

Family

ID=9921954

Family Applications (2)

Application Number Title Priority Date Filing Date
HN2002000253A HN2002000253A (es) 2001-09-12 2002-09-11 Uso de una combinacion de compuestos en un inhalador de polvo seco
HN2002000254A HN2002000254A (es) 2001-09-12 2002-10-11 Uso de compuestos en un inhalador de polvo seco

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HN2002000253A HN2002000253A (es) 2001-09-12 2002-09-11 Uso de una combinacion de compuestos en un inhalador de polvo seco

Country Status (34)

Country Link
US (3) US20030064031A1 (es)
EP (1) EP1427414A1 (es)
JP (1) JP2005505560A (es)
KR (1) KR20040036940A (es)
CN (1) CN1553801A (es)
AP (2) AP2002002623A0 (es)
AR (2) AR036473A1 (es)
BG (1) BG108569A (es)
BR (1) BR0212449A (es)
CA (1) CA2457717A1 (es)
CZ (1) CZ2004310A3 (es)
EA (1) EA006742B1 (es)
EC (1) ECSP045018A (es)
EE (1) EE200400078A (es)
GB (1) GB0122031D0 (es)
HN (2) HN2002000253A (es)
HR (1) HRP20040162A2 (es)
HU (1) HUP0401890A3 (es)
IL (1) IL160380A0 (es)
IS (1) IS7151A (es)
MA (1) MA27062A1 (es)
MX (1) MXPA04002354A (es)
NO (1) NO20041011L (es)
NZ (1) NZ530929A (es)
OA (1) OA12660A (es)
PA (2) PA8554601A1 (es)
PE (2) PE20030443A1 (es)
PL (1) PL368736A1 (es)
SK (1) SK1272004A3 (es)
SV (2) SV2004001227A (es)
TN (1) TNSN04040A1 (es)
TW (1) TW200602054A (es)
WO (2) WO2003022275A1 (es)
ZA (1) ZA200401002B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
JP2006513235A (ja) * 2002-12-31 2006-04-20 ネクター セラピューティクス 真菌感染症療法のためのエアゾール化可能な医薬製剤
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
CA2623882A1 (en) * 2005-09-28 2007-04-05 Merck Frosst Canada Ltd. Aerosol powder formulation comprising sieved lactose
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR200909788A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
CN105121439A (zh) 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物
KR20150076005A (ko) 2013-12-26 2015-07-06 삼성디스플레이 주식회사 액정 표시 장치
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물
RS58897B1 (sr) * 2014-09-15 2019-08-30 Verona Pharma Plc Tečna inhalaciona formulacija koja sadrži rpl554

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282167B6 (sk) * 1995-06-06 2001-11-06 Pfizer Inc. Tricyklické 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a] pyridíny a farmaceutický prostriedok na ich báze
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren

Also Published As

Publication number Publication date
PA8554701A1 (es) 2003-09-17
TNSN04040A1 (fr) 2006-06-01
MA27062A1 (fr) 2004-12-20
SV2004001227A (es) 2004-02-24
CA2457717A1 (en) 2003-03-20
PA8554601A1 (es) 2003-09-17
CN1553801A (zh) 2004-12-08
ZA200401002B (en) 2005-02-07
HUP0401890A3 (en) 2008-03-28
WO2003022275A1 (en) 2003-03-20
NZ530929A (en) 2006-08-31
MXPA04002354A (es) 2004-06-29
BG108569A (bg) 2005-02-28
EE200400078A (et) 2004-06-15
PE20030509A1 (es) 2003-06-23
SK1272004A3 (sk) 2005-03-04
IL160380A0 (en) 2004-07-25
JP2005505560A (ja) 2005-02-24
AP2002002623A0 (en) 2002-09-30
EA200400301A1 (ru) 2004-06-24
HUP0401890A2 (hu) 2004-12-28
TW200602054A (en) 2006-01-16
AR036473A1 (es) 2004-09-08
SV2004001226A (es) 2004-02-24
HRP20040162A2 (en) 2004-08-31
HN2002000253A (es) 2003-04-07
BR0212449A (pt) 2004-08-17
US20050232871A1 (en) 2005-10-20
OA12660A (en) 2006-06-19
KR20040036940A (ko) 2004-05-03
EA006742B1 (ru) 2006-04-28
US20030064031A1 (en) 2003-04-03
CZ2004310A3 (cs) 2005-02-16
ECSP045018A (es) 2004-04-28
IS7151A (is) 2004-02-13
AP2002002624A0 (en) 2002-09-30
GB0122031D0 (en) 2001-10-31
WO2003022279A1 (en) 2003-03-20
PL368736A1 (en) 2005-04-04
NO20041011L (no) 2004-03-10
EP1427414A1 (en) 2004-06-16
AR036474A1 (es) 2004-09-08
PE20030443A1 (es) 2003-05-17
US20030064034A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
HN2002000254A (es) Uso de compuestos en un inhalador de polvo seco
TW200637605A (en) Oral compositions containing extracts of rosmarinus and related methods
UY26383A1 (es) "compuestos farmacéuticamente activos"
ATE264102T1 (de) Nicotin enthaltende pharmazeutische zusammensetzungen mit schneller transmukosaler absorption
TWI340039B (en) Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
IL168279A (en) Use of liposomal and aminoglycoside composition to prepare a drug for the treatment or improvement of infection
AU2002303425A1 (en) Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
DE60224111D1 (de) Bausatz zur Herstellung einer Verabreichungsform zur Abgabe einer bioaktiven Substanz
PE20100743A1 (es) Nuevos procedimientos y formulaciones
SI1496858T1 (sl) Inhalacijski komplet, ki obsega inhalabilen prah tiotropija
EE05301B1 (et) Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
BR0314271A (pt) Forma de dosagem oral sólida útil para administração oral transmucosal, e, métodos de reduzir apetências por nicotina, e, uso de tabaco
HUP0400988A3 (en) Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
ECSP034678A (es) Dentifrico que contiene zinc de astringencia reducida
US20080032595A1 (en) Stuffed animal with massager/vibrating device reception
PA8586301A1 (es) Formulaciones de liberacion prolongada en forma de suspension
EE200100377A (et) Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena
DE50212646D1 (de) Verwendung von selenithältigen verbindungen zur topischen oder bukkalen anwendung
AU2002231811A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
HN2002000050A (es) Compuestos farmaceuticamente activos
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
ZA200205694B (en) Treatment of diabetic ulcers.
CR7270A (es) Uso de compuestos en un inhalador de polvo seco
EP1699466A4 (en) NEW CONNECTIONS AS METAL CHELATORS
UY27441A1 (es) Uso de compuestos en un inhalador de polvo seco.